AZ buys in before Summit's peak?

AstraZeneca is investing US$2 billion (A$2.9 billion) to gain a share of Summit Therapeutics and evaluate the Keytruda challenger ivonescimab in combination with AZ’s antibody-drug conjugates (ADCs).

To see the whole article please log in.

Simon Webster

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

Retype password

Not a member? Sign up here